156 related articles for article (PubMed ID: 10483843)
21. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD.
Dupaul GJ; Weyandt LL; Rossi JS; Vilardo BA; O'Dell SM; Carson KM; Verdi G; Swentosky A
J Atten Disord; 2012 Apr; 16(3):202-20. PubMed ID: 22166471
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
[TBL] [Abstract][Full Text] [Related]
23. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
[TBL] [Abstract][Full Text] [Related]
24. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.
Adler LA; Alperin S; Leon T; Faraone S
Postgrad Med; 2014 Sep; 126(5):17-24. PubMed ID: 25295646
[TBL] [Abstract][Full Text] [Related]
25. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.
Scheffer RE; Kowatch RA; Carmody T; Rush AJ
Am J Psychiatry; 2005 Jan; 162(1):58-64. PubMed ID: 15625202
[TBL] [Abstract][Full Text] [Related]
26. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
[TBL] [Abstract][Full Text] [Related]
27. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
28. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
[TBL] [Abstract][Full Text] [Related]
30. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
[TBL] [Abstract][Full Text] [Related]
31. Central nervous system stimulants for secondary attention deficit-hyperactivity disorder after paediatric traumatic brain injury: a rationale and protocol for single patient (n-of-1) multiple cross-over trials.
Senior HE; McKinlay L; Nikles J; Schluter PJ; Carmont SA; Waugh MC; Epps A; Lloyd O; Mitchell GK
BMC Pediatr; 2013 May; 13():89. PubMed ID: 23710976
[TBL] [Abstract][Full Text] [Related]
32. Four-year outcome in psychopharmacologically treated adults with attention-deficit/hyperactivity disorder: a questionnaire survey.
Lensing MB; Zeiner P; Sandvik L; Opjordsmoen S
J Clin Psychiatry; 2013 Jan; 74(1):e87-93. PubMed ID: 23419235
[TBL] [Abstract][Full Text] [Related]
33. Treatment of attention-deficit/hyperactivity disorder.
Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
[TBL] [Abstract][Full Text] [Related]
34. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder.
Nolan EE; Gadow KD; Sprafkin J
Pediatrics; 1999 Apr; 103(4 Pt 1):730-7. PubMed ID: 10103294
[TBL] [Abstract][Full Text] [Related]
35. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
37. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm.
Biederman J; Fried R; Hammerness P; Surman C; Mehler B; Petty CR; Faraone SV; Miller C; Bourgeois M; Meller B; Godfrey KM; Reimer B
J Psychiatr Res; 2012 Apr; 46(4):484-91. PubMed ID: 22277301
[TBL] [Abstract][Full Text] [Related]
38. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder.
Efron D; Jarman FC; Barker MJ
J Paediatr Child Health; 1998 Jun; 34(3):288-92. PubMed ID: 9633980
[TBL] [Abstract][Full Text] [Related]
39. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
Findling RL; Ginsberg LD; Jain R; Gao J
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):649-62. PubMed ID: 20035583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
